These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 27488725)

  • 21. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Risk and solutions to chimeric antigen receptor-engineered T cell-based cancer immunotherapy].
    Zhang MM; Jia DF; Diao Y
    Yao Xue Xue Bao; 2016 Jul; 51(7):1032-8. PubMed ID: 29896949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.
    Ghoneim HE; Zamora AE; Thomas PG; Youngblood BA
    Trends Mol Med; 2016 Dec; 22(12):1000-1011. PubMed ID: 27825667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming key challenges in cancer immunotherapy with engineered T cells.
    Arcangeli S; Mestermann K; Weber J; Bonini C; Casucci M; Hudecek M
    Curr Opin Oncol; 2020 Sep; 32(5):398-407. PubMed ID: 32796230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?
    Hombach AA; Abken H
    Expert Rev Clin Immunol; 2017 Feb; 13(2):151-155. PubMed ID: 27546707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.
    Zhang M; Zhang DB; Shi H
    Immunotherapy; 2017 Sep; 9(10):851-861. PubMed ID: 28877629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T Cell Genesis: In Vitro Veritas Est?
    Brauer PM; Singh J; Xhiku S; Zúñiga-Pflücker JC
    Trends Immunol; 2016 Dec; 37(12):889-901. PubMed ID: 27789110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput sequencing of the immune repertoire in oncology: Applications for clinical diagnosis, monitoring, and immunotherapies.
    Ye B; Smerin D; Gao Q; Kang C; Xiong X
    Cancer Lett; 2018 Mar; 416():42-56. PubMed ID: 29247824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering better immunotherapies via RNA interference.
    Sioud M
    Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.
    Jin C; Yu D; Essand M
    Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing adoptive T cell immunotherapy with microRNA therapeutics.
    Ji Y; Hocker JD; Gattinoni L
    Semin Immunol; 2016 Feb; 28(1):45-53. PubMed ID: 26710685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TCR-engineered T cells to treat tumors: Seeing but not touching?
    Debets R; Donnadieu E; Chouaib S; Coukos G
    Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
    Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
    Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance.
    Wellhausen N; Baek J; Gill SI; June CH
    Nat Rev Cancer; 2024 Sep; 24(9):614-628. PubMed ID: 39048767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.